Surging global demand for metabolic and obesity treatments has exposed yield limitations in traditional batch-run bioreactors. Contract Development and Manufacturing Organizations (CDMOs) are investing heavily in continuous-flow synthesis facilities to increase throughput.
Process Intensification
Continuous bioprocessing allows for footprint reductions of up to 70 percent while maintaining constant output metrics. Real-time process analytical technology (PAT) ensures stringent quality control without requiring post-batch downtime.
Supply Chain Bottlenecks
Primary constraints have migrated upstream to raw peptide inputs and specialized auto-injector device assembly lines, prompting vertical integration across major pharmaceutical balance sheets.